KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Long-Term Debt Repayments (2018)

Esperion Therapeutics' Long-Term Debt Repayments history spans 1 years, with the latest figure at $153000.0 for Q3 2018.

  • For Q3 2018, Long-Term Debt Repayments changed N/A year-over-year to $153000.0; the TTM value through Dec 2018 reached $1.0 million, changed N/A, while the annual FY2025 figure was $54.9 million, 73.86% down from the prior year.
  • Long-Term Debt Repayments reached $153000.0 in Q3 2018 per ESPR's latest filing, down from $451000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $451000.0 in Q2 2018 to a low of $153000.0 in Q3 2018.